Immunovant, Inc.
IMVT
$41.82
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.69M | 17.27M | 15.44M | 17.51M | 26.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.32M | 159.55M | 114.36M | 131.76M | 127.22M |
| Operating Income | -160.32M | -159.55M | -114.36M | -131.76M | -127.22M |
| Income Before Tax | -153.22M | -150.70M | -109.08M | -125.91M | -119.70M |
| Income Tax Expenses | -- | -2.84M | 1.55M | 594.00K | 913.00K |
| Earnings from Continuing Operations | -153.22M | -147.86M | -110.64M | -126.50M | -120.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.22M | -147.86M | -110.64M | -126.50M | -120.61M |
| EBIT | -160.32M | -159.55M | -114.36M | -131.76M | -127.22M |
| EBITDA | -160.23M | -159.46M | -114.26M | -131.66M | -127.12M |
| EPS Basic | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 |
| Normalized Basic EPS | -0.47 | -0.46 | -0.38 | -0.45 | -0.44 |
| EPS Diluted | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 |
| Normalized Diluted EPS | -0.47 | -0.46 | -0.38 | -0.45 | -0.44 |
| Average Basic Shares Outstanding | 205.55M | 203.71M | 181.51M | 173.64M | 170.87M |
| Average Diluted Shares Outstanding | 205.55M | 203.71M | 181.51M | 173.64M | 170.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |